Facebook
Twitter
LinkedIn
WhatsApp

Stage 4 Cancer

Stage 4, Stage IV metastatic cancer

“Metastases cancer” or stage 4 cancer, is the medical term for describing a condition where a tumor originating in a certain organ, “primary tumor”, is identified in another organ or in a distant location from the original organ, e.g., metastases of breast cancer can be found in the lungs, brain, bones and liver.

It is important to note, metastases are the same type of the original primary tumor, even if its location is in distant organs and so are the treatments regarded as such, for example, a treatment for a metastatic lung cancer that has spread to the liver, is determined by the treatment for metastatic lung cancer and not by the treatment for liver cancer.

Metastases formation

Cancer cells of the primary tumor can be released into the bloodstream and lymphatic system and circulate to distant organs or adjacent organs and tissues to the primary tumor and “settle” in them and grow.

There are different types of cancer which is known where metastases can be formed, for example,

  • Breast cancer can spread to the bones, brain, liver and lungs
  • Lung cancer can spread to the brain, bones, liver and kidney
  • Prostate cancer can spread to the bones
  • Colon cancer, rectal cancer, colorectal cancer can spread to the liver and lungs
Breast cancer can spread to the bones, brain, liver and lungs
Breast cancer can spread to the bones, brain, liver and lungs

Stage IV metastatic cancer and recovery

In the vast majority of the metastatic cases, the treatments do not cure. Treatment goals are slowing tumor growth rate, prolonging life and reducing the symptoms of the disease, improving the quality of life of the patient.

The efficacy of the treatments is affected by many factors, among them are the type of cancer, number of metastases (also called “lesions”) and their location, how much cancer the patient has in his or her body, growth rate of the tumor lesions, medical history of the patient, background diseases, microenvironment between the tumor cells themselves, resistance the tumor has developed to previous treatments and other.

Advanced treatments and clinical trials for stage 4

The National Cancer Institute (NCI) highlights the fact that for a certain group of metastatic cancer patients, the best treatment option is to join one of the many clinical trials existing worldwide aiming to increase their chances of therapeutic success.

This is also recommended by the USA national comprehensive cancer network, NCCN,  (USA national comprehensive cancer network)

“Patients with cancer should be encouraged to participate in clinical trials during all aspects of their diagnosis and treatment”

Currently, every patient will be offered the standard protocols described above. Sometimes the oncologist may suggest integrating these therapies with trials carried out in the Institute.

Advances in cancer therapies may be found in clinical trials prescribing cutting edge, interesting drugs, some of which have already been recognized by the FDA (US Food & Drug Administration) as “breakthrough treatments” and require further information input before being finally and fully approved.

An entire world of clinical trials and compassionate drugs and treatments are open and available worldwide. It is important to know which cutting edge treatments exist which patients can gain far more from them than the standard care offered.

For most patients with stage 4 metastatic cancer, current treatments are insufficiently effective. This gives rise to the need for innovative strategies with greater efficacy in fighting the disease.

Read our publications on innovative treatments for stage 4 metastatic cancer:

To check if our service suits your case
We need to talk

Improve therapeutic outcomes, prolong life and quality of life, is our main business.
We support access to and expand cancer treatments beyond the standard of care, with the most advanced and innovative treatment options in the world, personally matching the individual cancer patient’s medical condition and with the support of top tier oncologists.

Article categories

קטגוריות המאמרים

Popular topics

Facebook
Twitter
LinkedIn
WhatsApp

Prostate Cancer Breakthrough Drug Combination for Metastatic Patients

Background

Despite the advances and strides that modern medicine has made, prostate cancer treatment options remain to be fairly reserved.

However, the day is finally here that more methods of treatment could be explored especially for tough and persistent prostate cancer cases.

According to new revolutionary research in the field of cancer research led by The Institute of Cancer Research, London, a drug combination could effectively block two cancer growth signals at once in this type of cancer.

What this means is that this drug combination is effective for men who suffer from aggressive tumor growth and those who lack the PTEN gene which is a tumor suppressor.

The surprising findings:  

These new findings published by the lancet show promising results in combining ipatasertib plus abiraterone plus prednisone/prednisolone when it comes to treating prostate cancer.

The IPATential150 study varied its data in more than two dozen countries with 1,101 patients half of which lack the PTEN gene.

The result shows that combining ipatasertib with abiraterone and prednisolone had reduced the death risk by 23 percent compared to the placebo plus abiraterone plus prednisone/prednisolone.

Moreover, almost two-thirds of patients who lacked the PTEN gene which was useful against the tumors saw their tumor getting smaller compared to those in the group that took placebo plus abiraterone plus prednisone/prednisolone where only 39% of patients reported smaller tumors.

What’s even more promising is that the complete remission rate more than tripled with the group that combined Ipatasertib.

No sign of the disease was found in 19 percent of the patients that combined the drug whereas only 6 percent of the patients recovered taking placebo plus abiraterone plus prednisone/prednisolone.

Why this drug combination works:

A follow-up study is required to fully test the safety and efficiency of this method.

However, the findings show a clear win for combing Ipatasertib with these two drugs. It also shows that there is hope for men who are suffering from aggressive and relentless tumors.

The way that this works is by blocking the signals that prompt the growth of tumors.

This issue is something that men who suffer from prostate cancer who lack the PTEN gene fear.

However, with these new findings, it is highly likely that we are going to see a significant drop in mortality rates for prostate cancer as well as increased recovery rates.

Better hope for the future: 

Prostate cancer is the number one most common cancer that men suffer from.

Over a million cases worldwide every year could see new hope for the future thanks to this new study that offers a new way to treat prostate cancer.

Prostate cancer is a looming threat and danger to all men especially those who are prone to getting it.

Now with the new advances in science, we can finally see the light at the end of the tunnel and keep our hopes high.

Talk to us so see if we can help you to actually get the most advanced treatments

TRIAL•IN Pharma

Because we, do not give up on life!

Contact us 24/7 –

Call center +44.2082.426.039

References:

More about prostate cancer>>

Prostate Cancer Breakthrough Drug Combination for Metastatic Patients
Prostate Cancer Breakthrough Drug Combination for Metastatic Patients

No Cost service compatibility check
Please fill in the details and we will back to you as soon as possible

Improving therapeutic success, extending life and quality of life are our main business. We extend to metastatic cancer patients and patients with brain tumors, the most advanced treatment options in the world and the best experts in Israel and abroad.

Article categories

קטגוריות המאמרים

Popular topics